Ledipasvir belongs to a promising new class of
DAA drugs that work by blocking the NS5A protein, which the hepatitis C virus also needs to replicate.
Not exact matches
The researchers estimate that if the cost of the new
DAAs are equivalent to other new HCV antiviral
drugs then treatment rates would require an annual treatment budget of US $ 3.2 million in Edinburgh and approximately $ 50 million in Melbourne and Vancouver.
A modeling study by Massachusetts General Hospital (MGH) investigators finds that the availability of directly - acting antiviral (
DAA)
drugs to treat hepatitis C virus (HCV) infection could allow the transplantation of livers from HCV - positive...